Core Insights - Tevogen Bio has entered into an agreement with CD8 Technology Services for the development and/or acquisition of a turn-key facility to support pre-clinical research and GMP cell therapy production capabilities [1][2] - The agreement aims to accelerate development timelines, maintain operational agility, and control costs, addressing capital barriers typically faced in building GMP capabilities at scale [2][3] - The initial term of the agreement is 12 months, with automatic renewal, aligning with previously announced topline forecasts [2][6] Company Strategy - Tevogen Bio will provide primary staff and operations for the new facility, which is a significant step in expanding its infrastructure to support its pipeline of off-the-shelf, genetically unmodified CD8+ T cell therapeutics [3] - The agreement formalizes a previously announced letter of intent and is associated with Dr. Manmohan Patel, who owns more than 5% of the company's common stock [3] Future Outlook - Specific details regarding the facility, including scope of work, costs, and timelines, will be outlined in future work orders [3][6] - The agreement is expected to facilitate in-house cell therapy production capabilities, aligning with the company's long-term strategic goals [6]

Core Insights - Tevogen Bio has entered into an agreement with CD8 Technology Services LLC to develop a turn-key facility for in-house pre-clinical research and GMP cell therapy production capabilities [2][3] - The agreement is part of Tevogen Bio's long-term strategy to enhance development timelines, maintain operational flexibility, and control costs [3] - This milestone is seen as a significant step in expanding Tevogen Bio's infrastructure to support its pipeline of off-the-shelf, genetically unmodified CD8+ T cell therapeutics [4] Agreement Details - The agreement has an initial term of 12 months and will automatically renew, aligning with previously announced topline forecasts [3] - Tevogen Bio will provide the primary staff and operations for the facility, which is expected to help overcome capital barriers typically faced in building GMP capabilities at scale [3][4] - Specific details regarding the facility, including scope of work, costs, and timelines, will be outlined in future work orders [4] Leadership Commentary - Ryan Saadi, CEO of Tevogen Bio, emphasized the importance of this agreement in advancing the company's mission to help patients and in recognizing long-term shareholders [4]

WARREN, N.J., April 15, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced the commission of Databricks, Inc., a leader in data, analytics and artificial intelligence (AI), with an aim to accelerate the development of PredicTcell, the Company’s proprietary AI-driven target prediction model for precision immunotherapy. Databricks will provide a dedicated data engineering team and its expertise in building, scaling, and governing data and AI systems. T ...

Group 1 - Tevogen Bio Holdings Inc. will have its CEO, Dr. Ryan Saadi, participate in BioNJ's Fifteenth Annual Bio Partnering Conference, focusing on strategies for adapting to market volatility [1][2] - The conference aims to foster strategic partnerships and drive funding within the biopharmaceutical industry, ultimately advancing medical innovation [2][3] - Dr. Saadi emphasized the importance of addressing market volatility and its impact on patient outcomes, aligning with Tevogen Bio's mission to enhance accessibility to lifesaving treatments [3] Group 2 - The conference will feature a dynamic agenda including 1:1 partnering sessions, company pitch presentations, and extensive networking opportunities designed for growth and collaboration [3] - BioNJ President and CEO Debbie Hart expressed excitement for the panel discussion, highlighting the potential for attendees to gain actionable insights [3]

Core Insights - Tevogen Bio Holdings Inc. will participate in BioNJ's Fifteenth Annual Bio Partnering Conference, focusing on strategies for adapting to market volatility [1][2] - The conference aims to foster strategic partnerships and drive funding within the biopharmaceutical industry, ultimately advancing medical innovation [2][3] Company Participation - CEO Dr. Ryan Saadi will be featured in a panel discussion titled "Paths to Liquidity: Strategies for Adapting to a Volatile Market" [1] - The panel will include notable industry figures from J.P. Morgan Private Bank, RSM US, and Cantor Fitzgerald, indicating a strong representation of financial expertise [1] Industry Context - The biotechnology industry is currently facing market volatility, which could impact patient outcomes, highlighting the importance of discussions at the conference [3] - The conference will include various activities such as 1:1 partnering sessions, company pitch presentations, and extensive networking opportunities, designed to support growth and collaboration in the industry [3]

Core Insights - Tevogen Bio Holdings Inc. has launched a new initiative called Tevogen Generics to address the increasing focus on pharmaceutical affordability in the U.S. [1] - The initiative aims to expedite domestic manufacturing of unbranded pharmaceuticals and active pharmaceutical ingredients (APIs) to enhance national self-reliance in vital treatments [2] - Tevogen Generics is the third strategic pillar of Tevogen Bio, alongside its existing operations in specialty immunotherapy and artificial intelligence [3][7] Company Leadership - Sadiq Khan, the Chief Commercial Officer, has been appointed as the Interim Head of Tevogen Generics, bringing extensive experience in global commercial operations [2] Strategic Objectives - The primary goal of Tevogen Generics is to make high-quality, essential medicines accessible to all, aligning with national interests in healthcare affordability [7]

Core Viewpoint - Tevogen Bio Holdings Inc. is launching Tevogen Generics to address the increasing national focus on pharmaceutical affordability, coinciding with recent tariff-related statements from President Donald Trump [1][2]. Group 1: Company Initiatives - Tevogen Generics is established as the third strategic pillar of Tevogen Bio Holdings Inc., alongside Tevogen Bio and Tevogen.AI [3][7]. - The initiative aims to expedite domestic manufacturing of unbranded pharmaceuticals and active pharmaceutical ingredients (APIs), enhancing national self-reliance in vital treatments [2]. Group 2: Leadership and Management - Sadiq Khan, the Chief Commercial Officer, has been appointed as the Interim Head of Tevogen Generics, bringing decades of experience in global commercial operations [2].

Core Insights - Tevogen Bio Holdings Inc. is focused on immunotherapy and artificial intelligence, with recent presentations highlighting their advancements in AI-driven technology for T cell therapies [1][3][4] Company Overview - Tevogen Bio is a clinical-stage specialty immunotherapy company developing off-the-shelf, genetically unmodified precision T cell therapies aimed at treating infectious diseases and cancers [4] - The company has reported positive safety data from its proof-of-concept clinical trial and owns key intellectual property assets, including three granted patents and multiple pending patents related to artificial intelligence [4] Recent Developments - Mittul Mehta, the Chief Information Officer, presented at the AI x Bio Philly event, showcasing Tevogen.AI's technology that accelerates the discovery and development of precision T cell therapies [1][3] - The proprietary technology utilizes computational modeling to predict T cell receptor engagement with immunologically active HLA+ peptide complexes [3] Industry Context - The AI x Bio Philly event gathered innovators, entrepreneurs, and investors to discuss the impact of AI on biotechnology, indicating a growing intersection between these fields [2]

Core Viewpoint - Tevogen Bio Holdings Inc. is advancing its efforts in immunotherapy and artificial intelligence, particularly through its proprietary AI-driven technology aimed at enhancing the development of precision T cell therapies [1][3]. Company Overview - Tevogen Bio is a clinical-stage specialty immunotherapy company focused on developing off-the-shelf, genetically unmodified precision T cell therapies to address infectious diseases and cancers, targeting significant unmet needs in large patient populations [4]. - The company has reported positive safety data from its proof-of-concept clinical trial and owns key intellectual property assets, including three granted patents and numerous pending patents related to artificial intelligence [4]. Recent Developments - Mittul Mehta, the Chief Information Officer, presented at the AI x Bio Philly event, showcasing Tevogen.AI's technology that utilizes computational modeling to predict T cell receptor engagement with immunologically active HLA+ peptide complexes [1][3]. - The AI x Bio Philly event, hosted by various organizations, gathered innovators and investors to discuss the impact of AI on biotechnology [2]. Leadership and Vision - Tevogen Bio is led by a team of experienced industry leaders and scientists, emphasizing the importance of accessible personalized therapeutics as the next frontier in medicine [5]. - The leadership believes that innovative business models are essential for sustaining medical innovation in the current healthcare landscape [5].

Core Insights - Tevogen Bio Holdings Inc. is focused on advancing patient-centric solutions through immunotherapy and artificial intelligence, with a commitment to developing off-the-shelf, genetically unmodified T cell therapeutics for infectious diseases and cancers [1] - The company emphasizes the significant insider ownership, with approximately 74% of outstanding shares held by executive officers and board members, indicating strong confidence in the company's mission and progress [2][3] Company Overview - Tevogen's clinical-stage immunotherapy, Tevogen Bio, aims to create innovative treatments for infectious diseases and cancers [1] - The artificial intelligence initiative, Tevogen.AI, is designed to enhance drug discovery, clinical trial efficiency, and patient access [1] Insider Ownership - Insiders have only sold shares to meet tax obligations related to restricted stock vesting, showcasing their commitment to the company [2] - The high level of insider ownership is noted as a unique advantage compared to other companies in the industry [2] Market Position - The company operates solely in the U.S. and is described as tariff-insensitive, which may provide a buffer against current market volatility [3]